Superior Planning, LLC’s Sagimet Biosciences SGMT Stock Holding History

Superior Planning, LLC’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$751	Buy	+76	New	+$698	﹤0.01%	1818

Other funds holding SGMT

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Superior Planning, LLC's SGMT Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Sagimet Biosciences (SGMT) in Q3 2026: 76 shares worth $751. The stake represents ﹤0.01% of the portfolio and ranks #1818 among its holdings.

61 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.

Superior Planning, LLC held 76 shares of Sagimet Biosciences worth $751 as of Q3 2026.
Sagimet Biosciences was a new Superior Planning, LLC position in Q3 2026.
Sagimet Biosciences made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1818 holding.
61 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.